Proceedings: Prevention by Ca-antagonistic compounds (verapamil, D 600) of coronary smooth muscle contractures due to treatment with cardiac glycosides.
D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D002118:Calcium / Q000037:antagonists & inhibitors*; D002301:Cardiac Glycosides / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003331:Coronary Vessels / Q000187:drug effects*; D004176:Dipyridamole / Q000494:pharmacology; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects*; D011299:Prenylamine / Q000494:pharmacology; D013806:Theophylline / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology*
D002301:Cardiac Glycosides; D002110:Caffeine; D004176:Dipyridamole; D013806:Theophylline; D014700:Verapamil; D011299:Prenylamine; D002118:Calcium